Alexion is a global biopharmaceutical company focused on developing and delivering life-transforming therapies for patients with devastating and rare diseases. Patients with these life-threatening diseases often have no effective treatment options, and they and their families suffer with little hope. Our goal is to deliver medical breakthroughs where none currently exist. We are driven because we know people's lives depend on our work.
Alexion developed Soliris® (eculizumab) from the laboratory through commercialization for the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS), two life-threatening, ultra-rare disorders. Today, Soliris is approved in nearly 50 countries for PNH and nearly 40 countries for aHUS. Download Soliris prescribing information.
As we continue to expand our operations into additional countries, Alexion is advancing the most robust rare disease pipeline in the biotech industry, with highly innovative product candidates in multiple therapeutic areas. Alexion is establishing a premier global metabolic rare disease franchise with two potential therapies in late-stage development, Strensiq™ (asfotase alfa) for hypophosphatasia (HPP) and Kanuma™ (sebelipase alfa) for Lysosomal Acid Lipase Deficiency (LAL Deficiency, or LAL-D). Strensiq has been approved in the EU and Japan for the treatment of patients with HPP, and Kanuma has been approved in the EU for the treatment of patients with LAL-D. In addition, as the global leader in complement inhibition, we are strengthening and broadening our portfolio of complement inhibitors across diverse platforms, including evaluating potential indications for Soliris in additional severe and ultra-rare disorders.
Alexion was established in the U.S. in 1992 and became a public company in 1996 (NASDAQ: ALXN). We were added to the NASDAQ-100 Index in 2011 and to the Standard & Poor's 500 Index in 2012.
Our global headquarters and research operations are in Cheshire, Conn., and will move to New Haven, Conn. in 2015. Alexion's more than 2,800 employees serve patients in 50 countries.